Diabetes Digest - DiabetesontheNet

This site is intended for healthcare professionals only

Diabetes Digest

Editor's pick

My patient is on a statin. Why are they not also on an SGLT2 inhibitor?

Vinod Patel highlights the costs associated with diabetes complications and the savings that can be made by preventing them.

Latest content

Healthcare costs of type 2 diabetes-related complications

Finnish study estimates mean costs of €11,798 in the first year after an event.

Early glycaemic control and subsequent glycaemic stability improve cardiovascular outcomes in type 2 diabetes

Poor control in the first year of diagnosis and greater HbA1c variability thereafter confer the greatest risk.

Simulated cost-effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors

Cardiovascular benefits make SGLT2 inhibitors highly cost-effective in people with type 2 diabetes regardless of CVD history.

Cardiorenal effects of dapagliflozin according to renal function at initiation

Cardiorenal benefits of dapagliflozin are consistent across KDIGO risk categories, both in people with and without type 2 diabetes.

Ready-to-use glucagon as a treatment for hypoglycaemia

With new, more convenient formulations hitting the market, is glucagon ready to replace oral carbohydrate as the treatment of choice for hypoglycaemia?

Mini-dose glucagon to treat hypoglycaemia during Ramadan fasting

Mini-dose glucagon results in superior glycaemic control compared with oral carbohydrate in people who are fasting for Ramadan.

Gastrointestinal symptoms in people with type 1 diabetes

GI symptoms are common in people with type 1 diabetes, and the type of symptoms varies on the basis of age.

Hybrid closed-loop technology and glycaemic outcomes according to baseline HbA1c

Benefits seen across the range of starting HbA_1c, whether high or low.

Glycaemic control throughout the menstrual cycle in closed-loop technology users

Hybrid closed-loop system is effective throughout the menstrual cycle.

Overweight and obesity in people with type 1 diabetes

Daniel Flanagan reviews the long-term effects of increasing obesity rates in people with type 1 diabetes and asks what clinicians can do.

Prevalence of obesity and CKD in people with type 1 diabetes

Obesity rates are high and rising in people with type 1 diabetes and are associated with a higher risk of CKD versus the general population.

CGM initiation within 1 year of diagnosis improves long-term glycaemic control

Initiating CGM early may set a better glycaemic trajectory, with effects on long-term diabetes outcomes.

Latest events & on-demand videos

2022: 18th National Conference of the Primary Care Diabetes Society

📍National Conference Centre, Birmingham

23 November 2022 - 09:15am

24 November 2022 - 09:00am

Register now, save the date and share the news to your colleagues.

→ Face-to-Face, Event

2022: 15th Scottish Conference of the Primary Care Diabetes Society

📍DoubleTree by Hilton, Glasgow Central

25 October 2022 - 09:00am

Register now, save the date and share the news to your colleagues.

→ Face-to-Face, Event

2022: 12th Northern Ireland Conference of the Primary Care Diabetes Society

📍Hilton Templepatrick, Belfast

15 September 2022 - 09:00am

Register now, save the date, and share the news to your colleagues

→ Face-to-Face, Event

2022: 13th Welsh Conference of the Primary Care Diabetes Society

📍Jurys Inn Cardiff

Watch the live stream on – demand!

Previous

Next

Latest articles

My patient is on a statin. Why are they not also on an SGLT2 inhibitor?

Healthcare costs of type 2 diabetes-related complications

Early glycaemic control and subsequent glycaemic stability improve cardiovascular outcomes in type 2 diabetes

Simulated cost-effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors

Cardiorenal effects of dapagliflozin according to renal function at initiation

Ready-to-use glucagon as a treatment for hypoglycaemia

Mini-dose glucagon to treat hypoglycaemia during Ramadan fasting

For the latest news and articles

Sign up to all DiabetesontheNet journals

Follow us for all the latest news and updates in diabetes.

Resources

Journals

Useful information

© Copyright Omniamed Communications. All Rights Reserved
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom

;